A Phase 1b PK/PD Study to Demonstrate Antigen Elimination With RLYB212, a Monoclonal Anti-HPA-1a Antibody for FNAIT Prevention.

Christof GeisenErika FleckStephan Martin Gastón SchäferCarmen WalterSusanne BraeuningerJens Søndergaard JensenDouglas SheridanKiran PatkiRóisín ArmstrongBjorn SkogenFrank BehrensErhard SeifriedJens Kjeldsen-KraghMette KjærMichaela Köhm

Published in: Thrombosis and haemostasis (2024)

The data from this study are consistent with preclinical efficacy data and support the potential use of RLYB212 as a prophylactic treatment for FNAIT that prevents maternal HPA-1a alloimmunization during at-risk pregnancies.

Keyphrases

big data
stem cells
machine learning
pregnant women
preterm birth
bone marrow
climate change
cell therapy
data analysis
human health
birth weight
replacement therapy